Rita Businaro

Dr. Rita Businaro

School of Medicine, Sapienza University of Rome, Italy
orcid

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 April 2018 in Antioxidants
Verified
Journal Article
Open access
PDF file
APAlessandro Pinto
Alessandro Pinto
ABAlessio Bonucci
Alessio Bonucci
EMElisa Maggi
Elisa Maggi
MCMariangela Corsi
Mariangela Corsi
RBRita Businaro
Rita Businaro
The ketogenic diet, originally developed for the treatment of epilepsy in non-responder children, is spreading to be used in the treatment of many diseases, including Alzheimer’s disease. The main activity of the ketogenic diet has been related to improved mitochondrial function and decreased oxidative stress. B-Hydroxybutyrate, the most studied ketone body, has been shown to reduce the production of reactive oxygen species (ROS), improving mitochondrial respiration: it stimulates the cellular endogenous antioxidant system with the activation of nuclear factor erythroid-derived 2-related factor 2 (Nrf2), it modulates the ratio between the oxidized and reduced forms of nicotinamide adenine dinucleotide (NAD+/NADH) and it increases the efficiency of electron transport chain through the expression of uncoupling proteins. Furthermore, the ketogenic diet performs anti-inflammatory activity by inhibiting nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) activation and nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3 (NLRP3) inflammasome as well as inhibiting histone deacetylases (HDACs), improving memory encoding. The underlying mechanisms and the perspectives for the treatment of Alzheimer’s disease are discussed.

13 February 2006 in Journal of Neuroscience Research
Verified
Journal Article
Closed access
PDF file
RBRita Businaro
Rita Businaro
SLS. Leone
S. Leone
CFC. Fabrizi
C. Fabrizi
Guglielmo SorciGuglielmo Sorci
Guglielmo Sorci
Rosario DonatoRosario Donato
Rosario Donato
LFL. Fumagalli
L. Fumagalli

1 January 2014 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
Brigitta ButtariBrigitta Buttari
Brigitta Buttari
EPElisabetta Profumo
Elisabetta Profumo
LSLuca Segoni
Luca Segoni
DDDaniela D’Arcangelo
Daniela D’Arcangelo
SRStefania Rossi
Stefania Rossi
RRRachele Riganò
Rachele Riganò
Macrophages consist of two main subsets: the proinflammatory M1 subset and the anti-inflammatory M2 one. 7-oxo-cholesterol, the most abundant cholesterol autoxidation product within atherosclerotic plaque, is able to skew the M1/M2 balance towards a proinflammatory profile. In the present study, we explored the ability of the polyphenolic compound resveratrol to counteract the 7-oxo-cholesterol-triggered proinflammatory signaling in macrophages. Resveratrol-pretreated human monocyte-derived M1 and M2 macrophages were challenged with 7-oxo-cholesterol and analyzed for phenotype and endocytic ability by flow cytometry, for metalloproteinase- (MMP-) 2 and MMP-9 by gelatin zymography, and for cytokine, chemokine, and growth factor secretome by a multiplex immunoassay. We also investigated the NF-κB signaling pathway. In the M1 subset, resveratrol prevented the downregulation of CD16 and the upregulation of MMP-2 in response to 7-oxo-cholesterol, whereas in M2 macrophages it prevented the upregulation of CD14, MMP-2, and MMP-9 and the downregulation of endocytosis. Resveratrol prevented the upregulation of several proinflammatory and proangiogenic molecules in both subsets. We identified modulation of NF-κB as a potential mechanism implicated in 7-oxo-cholesterol and resveratrol effects. Our results strengthen previous findings on the immunomodulatory ability of resveratrol and highlight its role as potential therapeutic or preventive compound, to counteract the proatherogenic oxysterol signaling within atherosclerotic plaque.

Verified
Journal Article
Open access
PDF file
RVRomain Versele
Romain Versele
MCMariangela Corsi
Mariangela Corsi
Andrea FusoAndrea Fuso
Andrea Fuso
ESEmmanuel Sevin
Emmanuel Sevin
RBRita Businaro
Rita Businaro
PCPietra Candela
Pietra Candela
Alzheimer’s disease (AD) is characterized by the abnormal accumulation of amyloid-β (Aβ) peptides in the brain. The pathological process has not yet been clarified, although dysfunctional transport of Aβ across the blood–brain barrier (BBB) appears to be integral to disease development. At present, no effective therapeutic treatment against AD exists, and the adoption of a ketogenic diet (KD) or ketone body (KB) supplements have been investigated as potential new therapeutic approaches. Despite experimental evidence supporting the hypothesis that KBs reduce the Aβ load in the AD brain, little information is available about the effect of KBs on BBB and their effect on Aβ transport. Therefore, we used a human in vitro BBB model, brain-like endothelial cells (BLECs), to investigate the effect of KBs on the BBB and on Aβ transport. Our results show that KBs do not modify BBB integrity and do not cause toxicity to BLECs. Furthermore, the presence of KBs in the culture media was combined with higher MCT1 and GLUT1 protein levels in BLECs. In addition, KBs significantly enhanced the protein levels of LRP1, P-gp, and PICALM, described to be involved in Aβ clearance. Finally, the combined use of KBs promotes Aβ efflux across the BBB. Inhibition experiments demonstrated the involvement of LRP1 and P-gp in the efflux. This work provides evidence that KBs promote Aβ clearance from the brain to blood in addition to exciting perspectives for studying the use of KBs in therapeutic approaches.

1 November 2009 in Atherosclerosis
Verified
Journal Article
Closed access
RBRita Businaro
Rita Businaro
EPElisabetta Profumo
Elisabetta Profumo
ATAngela Tagliani
Angela Tagliani
Brigitta ButtariBrigitta Buttari
Brigitta Buttari
SLStefano Leone
Stefano Leone
RRRachele Riganò
Rachele Riganò

12 January 2012 in Journal of Alzheimer’s Disease
Verified
Journal Article
Closed access
PDF file
SRSerafino Ricci
Serafino Ricci
AFAndrea Fuso
Andrea Fuso
FIFlora Ippoliti
Flora Ippoliti
RBRita Businaro
Rita Businaro
Increasing evidence has been accumulating about the role of stress as an important challenge to the onset and progression of Alzheimer's disease (AD). The hippocampus, one of the areas of the brain damaged during AD, was the first brain region, besid